Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 26, 2017
What are the generic sources for dexamethasone and what is the scope of dexamethasone patent protection?
Dexamethasone is the generic ingredient in thirty-one branded drugs marketed by ECR, Phoenix Labs Ny, West-ward Pharms Int, Sun Pharm Inds, Roxane, Allergan, Watson Labs, Pvt Form, Novartis Pharms Corp, Whiteworth Town Plsn, Merck, Upsher Smith, Xspire Pharma, Par Pharm, Sti Pharma Llc, Wockhardt Eu Operatn, Larken Labs Inc, Organon Usa Inc, Impax Labs, Vintage Pharms, Solvay, Lyne, Allergan Herbert, Alpharma Us Pharms, Idt Australia Ltd, Watson Labs Teva, Mylan Labs Ltd, Ucb Inc, Fresenius Kabi Usa, Intl Medication, Teva Parenteral, Pharmafair, Luitpold, Wyeth Ayerst, Cent Pharms, Alcon, Abraxis Pharm, Bel Mar, Akorn, Dell Labs, Lyphomed, Bausch And Lomb, Sola Barnes Hind, Sandoz Inc, Aurobindo Pharma Ltd, Alcon Pharms Ltd, Perrigo Co Tennessee, and Novartis, and is included in one hundred and twenty-four NDAs. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.| Tradenames: | 31 |
| Patents: | 17 |
| Applicants: | 48 |
| NDAs: | 124 |
| Drug Master File Entries: see list | 39 |
| Suppliers / Packagers: see list | 37 |
| Bulk Api Vendors: see list | 76 |
| Clinical Trials: see list | 1,990 |
| Therapeutic Class: | Ophthalmic Agents |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | dexamethasone at DailyMed |
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,242,099 | Implants and methods for treating inflammation-mediated conditions of the eye | ► Subscribe | |||||||||||||
| 8,048,445 | Ocular implant made by a double extrusion process | ► Subscribe | |||||||||||||
| 8,828,446 | Method for reducing transplant rejection in the eye and intraocular implants for use therefor | ► Subscribe | |||||||||||||
| 8,071,120 | Methods for treating neovascularization and intravitreal implants | ► Subscribe | |||||||||||||
| 7,090,681 | Methods and apparatus for delivery of ocular implants | ► Subscribe | |||||||||||||
| 7,753,916 | Methods and apparatus for delivery of ocular implants | ► Subscribe | |||||||||||||
| 6,699,493 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor | ► Subscribe | |||||||||||||
| 7,468,065 | Apparatus for delivery of ocular implants | ► Subscribe | |||||||||||||
| 8,778,381 | Ocular implant made by a double extrusion process | ► Subscribe | |||||||||||||
| 7,625,582 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 7316601 | ► Subscribe | |||||||||||||
| Slovenia | 1776091 | ► Subscribe | |||||||||||||
| Hong Kong | 1082902 | ► Subscribe | |||||||||||||
| European Patent Office | 1339438 | ► Subscribe | |||||||||||||
| Mexico | PA05002841 | ► Subscribe | |||||||||||||
| Poland | 376478 | ► Subscribe | |||||||||||||
| New Zealand | 540451 | ► Subscribe | |||||||||||||
| European Patent Office | 1581193 | ► Subscribe | |||||||||||||
| Israel | 180865 | ► Subscribe | |||||||||||||
| European Patent Office | 1917957 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00552 | Netherlands | ► Subscribe | PRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727 | ||||||||||||
| 2012000081 | Germany | ► Subscribe | PRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727 | ||||||||||||
| C0012 | France | ► Subscribe | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 | ||||||||||||
| C/GB12/058 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,775 others who get our Drug Patent Expiration Alerts:
